Biological Institute examining Omicron characteristics in safety lab
Israel's BriLife vaccine will soon be evaluated for its effectiveness against the new COVID variant.
25-year-old Sharon Ben Hemo, a fourth-year student at the Faculty of Dentistry of Hadassah and Hebrew University, receives the IIBR's Brilife vaccine as part of the first phase of human trials in Hadassah University Medical Center, 08.11.2020(photo credit: HADASSAH UNIVERSITY MEDICAL CENTER)ByMAAYAN JAFFE-HOFFMANUpdated:
